New Treatment Standards in Uro-Oncological Diseases with High Unmet Need

Jeff Bova, Chief Commercial Officer at UroGen Pharma discusses the launch of their first FDA-approved treatment, the only non-surgical option for patients with low-grade upper tract urothelial carcinoma, or LG-UTUC. This is the first of UroGen medicines to demonstrate an industry-leading move towards more innovative, non-surgical options for patients.  He shares UroGen’s vision to fundamentally change the treatment model for some of the most devastating cancers by delivering better medicines to patients in ways never done before.

Jeff Bova, Chief Commercial Officer at UroGen Pharma.

Jeff is an experienced pharmaceutical industry executive with extensive leadership experience in national sales, marketing, and managed care. Jeff joined UroGen in 2017 as Vice President and Head of Commercial, and now serves as the Chief Commercial Officer. Prior to UroGen, Jeff held multiple senior-level sales leadership positions at Bayer Healthcare and most recently served as Vice President of Oncology Sales, where he led a field sales force of more than 200 in marketing brands. Jeff holds a master’s degree in business administration from Xavier University and a Bachelor of Science in finance and marketing from the University of Cincinnati.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.